What cancer diseases does Lorlatinib/Lorlatinib (Borina) mainly treat?

Lorlatinib/Lorlatinib (Lorlatinib) is a targeted drug mainly used to treat ALK-positive non-small cell lung cancer (NSCLC). Non-small cell lung cancer is the most common type of lung cancer, and about 3%-5% of patients carry ALK gene rearrangements. ALK gene rearrangement is caused by the fusion of the anaplastic lymphoma kinase gene (ALK) with other genes, resulting in abnormal proteins that can promote the growth and spread of cancer cells. Therefore, targeted therapy targeting ALK gene rearrangement has become the main method of treating ALK-positive non-small cell lung cancer.

Lorlatinib can effectively control the growth of ALK-positive non-small cell lung cancer by inhibiting the activity ofALK protein and blocking the proliferation and metastasis of cancer cells. Compared with early ALK inhibitors (such as crizotinib, icotinib, etc.), lorlatinib has stronger blood-brain barrier penetration ability and can effectively treat lung cancer patients with brain metastases. Therefore, lorlatinib has become a treatment option for patients with ALK-positive non-small cell lung cancer who have both primary lung tumors and brain metastases.

Lorlatinib is not only effective for newly treated ALK-positive lung cancer patients, but it can also provide an effective treatment option for patients who have developed resistance after treatment with other ALK inhibitors. Studies have shown that lorlatinib can overcome resistance in ALK inhibitor treatment and regain control of tumor progression. Therefore, lorlatinib is considered one of the "follow-up therapies" for the treatment of ALK-positive non-small cell lung cancer, especially for patients who have failed other treatment options.

It is worth noting that lorlatinib is not only suitable for treating lung cancer. As research continues, the use of lorlatinib in other cancer types has also been explored. For example, lorlatinib has also shown potential therapeutic effects in some patients with advanced ALK-positive tumors, including ALK-positive lymphoma, colorectal cancer, etc. Although these indications are still in clinical trials, they open up new therapeutic areas for the future development of lorlatinib.

References:https://en.wikipedia.org/wiki/Lorlatinib